Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 10;18(1):2526827.
doi: 10.1080/20523211.2025.2526827. eCollection 2025.

Beyond cost: a value-based framework for biosimilar procurement in emerging markets - the Thai experience

Anunchai Assawamakin  1 , Nilawan Upakdee  2 , Khachen Kongpakwattana  3 ; Hospital Pharmacist Consortium of Thailand
Affiliations

Beyond cost: a value-based framework for biosimilar procurement in emerging markets - the Thai experience

Anunchai Assawamakin et al. J Pharm Policy Pract. .

Abstract

Background: Biosimilars offer potential for increased access to critical biological therapies in emerging-markets like Thailand. However, making procurement decisions for these complex molecules requires considering multiple factors beyond cost. This study aimed to develop and test a context-specific, value-based procurement framework for biosimilars in Thailand using Multi-Criteria Decision Analysis (MCDA).

Methods: This study employed a mixed-methods approach, combining a literature review with expert consensus workshops. The literature review identified existing biosimilar selection criteria, which were mapped onto the Most Economically Advantageous Tender (MEAT) Value-Based Procurement (VBP) framework. Two expert consensus workshops were conducted to develop and refine a Thai-specific MCDA tool. The initial framework underwent a feasibility study in five hospitals across Thailand, with feedback incorporated into the refined version.

Results: The literature review yielded seven relevant studies, predominantly from established markets. The expert workshops produced a tailored MCDA tool with seven key criteria: Quality Assessment, Stability Assessment, Comparability Exercise, Indications and Extrapolation, Pharmacovigilance and Risk Management, Real-World Evidence and Switching Studies, and Other Considerations. Each criterion was weighted based on its perceived importance in the Thai context. The feasibility study resulted in refinements, such as adjusting criterion weights and incorporating flexibility for hospital-specific priorities.

Conclusion: This study presents a comprehensive, context-specific MCDA tool for biosimilar procurement in Thailand. By balancing scientific rigour with practical considerations, this framework has the potential to optimise biosimilar selection, enhancing access to vital biological therapies while ensuring quality and cost-effectiveness. The approach taken to develop this framework could serve as an initiative for other emerging markets seeking to improve their biosimilar procurement strategies.

Keywords: Biosimilars; Thailand; emerging markets; multi-criteria decision analysis; value-based procurement.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
Figure 2.
Figure 2.
Biosimilar MCDA evaluation flowchart.
See this image and copyright information in PMC

References

    1. Barbier, L., Simoens, S., Soontjens, C., Claus, B., Vulto, A. G., & Huys, I. (2021). Off-Patent biologicals and biosimilars tendering in Europe-A proposal towards more sustainable practices. Pharmaceuticals (Basel), 14(6), 10.3390/ph14060499 - DOI - PMC - PubMed
    1. Barbier, L., Vandenplas, Y., Boone, N., Huys, I., Janknegt, R., & Vulto, A. G. (2022). How to select a best-value biological medicine? A practical model to support hospital pharmacists. American Journal of Health-System Pharmacy, 79(22), 2001–2011. 10.1093/ajhp/zxac235 - DOI - PMC - PubMed
    1. Butani, D., Faradiba, D., Dabak, S. V., Isaranuwatchai, W., Huang-Ku, E., Pachanee, K., Soboon, B., Culyer, A. J., & Teerawattananon, Y. (2023). Expanding access to high-cost medicines under the universal health coverage scheme in Thailand: Review of current practices and recommendations. Journal of Pharmaceutical Policy and Practice, 16(1), 138. 10.1186/s40545-023-00643-z - DOI - PMC - PubMed
    1. Chhabra, H., Mouslim, M. C., Kashiramka, S., & Rathore, A. S. (2022). Dynamics of biosimilar uptake in emerging markets. Expert Opinion on Biological Therapy, 22(6), 679–688. 10.1080/14712598.2022.2076557 - DOI - PubMed
    1. Costin, J., Mouslim, M. C., Socal, M. P., & Trujillo, A. (2024). Exploring the influence of health insurance plans on biosimilar adoption rates. PharmacoEconomics - Open, 8(1), 115–118. 10.1007/s41669-023-00447-6 - DOI - PMC - PubMed

LinkOut - more resources